Join the webinar today, 3 July, 16:00 – 17:00 CEST
Preclinical testing can provide the necessary background or laboratory knowledge that may be used to generate hypotheses later assessed in clinical trials. The benefits of preclinical trials include developing new surgical procedures and hands-on training in new medical devices and prescription drugs. They are vital for assessing the safety profiles and potential efficacy of new therapeutics in development.
Preclinical in vivo experiments include animal testing at the preclinical stage under the central ethical dilemma of whether to use the animal model and ensure to limit its usage when necessary. We will discuss this dilemma further during this webinar and hear the experts’ opinions.
This webinar is organised by the ESICM Ethics (ETH) and Translational Biology (TransBio) Sections.
Learning Outcomes
- Evaluate if preclinical in vivo experiments can be replaced, reduced or refined.
- Overview of the knowledge advances in critical care from the preclinical in vivo experiments.
- Discuss the moral status of animals involved in preclinical studies.
Topics & Experts
“Preclinical in vivo experiments in Critical Care – how do we replace, reduce, and refine?”
Marcin OSUCHOWSKI
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center (AT).
“How have preclinical in vivo experiments contributed to knowledge advances in Critical Care “
Nicole JUFFERMANS
Erasmus University of Rotterdam (NL). Editor-in-Chief, Intensive Care Experimental (ICMx) Journal.
Moderators
John LAFFEY
Galway University Hospitals (IE). Chair, ESICM Translational Biology Section.
Jos LATOUR
Plymouth University (UK). Chair, ESICM Ethics Section.
